Payne et al. recently reported an excellent overview of a target-based approach to new antibacterial development and the lack of new antibacterial drugs in late-stage development several years ago 1 . This observation has also been made by the participants in the recent forum 2 of anti-infective research and development. Also, the Infectious Diseases Society of America recently identified six top-priority dangerous pathogens -extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae, Acinetobacter baumannii, Pseudomonas aeruginosa, vancomycin-resistant Enterococcus faecium, methicillin-resistant Staphylococcus aureus and Aspergillus species -for which there are few or no drugs in late-stage development. This could further limit future safe and effective choices for treating these infections Three of these six pathogens are antibiotic-resistant Gram-negative bacteria. Recently, antibacterial drugs against ESBLproducing Gram-negative bacteria accounted for ~15% (2 out of 13) of all antibacterial drugs undergoing development in Phase II trials or later clinical studies 3 . However, there are no drugs being developed against class C ESBL-producing Gram-negative bacteria. Here, we draw attention to important aspects of urgently needed antibacterial drugs against class C ESBL-producing Gram-negative bacteria, which have been overlooked by these reports. We also suggest that the category of ESBLs should be expanded.
ESBLs are a group of enzymes for which the substrate spectrum has extended to third-generation oxyimino-cephalosporins . Cefepime (a fourth-generation oxyiminocephalosporin) was also inactivated by KL, HD and CMY-19 ESBLs 5, 6, 8 . Rubinstein and Zhanel have noted that physicians are increasingly being forced to use the carbapenems (for example, imipenem or meropenem) and fluoroquinolones (for example, ciprofloxacin or levofloxacin) as first-line therapy for ESBL-producing Gram-negative bacteria; indeed, the situation will become even more severe as ESBL-producing organisms increasingly become concomitantly resistant to the fluoroquinolones 2 . However, we recently found that the CMY-10 ESBL had higher imipenemhydrolysing activity than OXA-23, a class D carbapenemase 7, 10 . Gram-negative bacteria producing such class C ESBLs could present a major therapeutic challenge, and so new antibacterial drugs against class C ESBLproducing Gram-negative bacteria are urgently needed.
To develop these antibacterial drugs, it is necessary to understand the operative mechanism of class C ESBLs to extend their substrate spectrum. Our kinetic data and crystal structure 7 of a plasmid-encoded class C ESBL (that is, CMY-10) clarify this mechanism. The region responsible for the extended substrate spectrum is the R2-loop (amino-acid residues 289-307) 7 . Our sequence alignment of four class C ESBLs shows that the R2-loop includes all regions responsible for the extended substrate spectrum in all class C ESBLs, compared with P99 (a class C non-ESBL) ( These natural mutations in the R2-loop can change the architecture of the active site in class C ESBLs, thereby affecting their hydrolysing activity. Owing to the deletion in CMY-10, for example, the R2-loop in the R2 active site (that is, the region that accommodates the R2 side-chain at C3 of the β-lactam nucleus in oxyimino-cephalosporins) displays noticeable structural alterations. The shortened path of the connection R2-loop between α10 and β11 induces the ~2.5 Å shift of α9 and α10 relative to the adjacent helix α11 in CMY-10 compared with both P99 (Ref. 11) and GC1 (Ref. 12) β-lactamases, thereby opening the gap between α9-α10 and α11 (Ref. 7) . Therefore, the bulky R2 side-chain of oxyimino-cephalosporins could fit snugly into the significant widening of the R2 active site in this way.
Clinically available β-lactamase inhibitors (for example, clavulanic acid, sulbactam or tazobactam) co-administered with less A lack of drugs for antibioticresistant Gram-negative bacteria effective β-lactams are effective against class A beta-lactamases, but have little or no activity against class C β-lactamases. Because Gram-negative bacteria producing class C ESBLs are becoming an increasingly common cause of nosocomial infections [5] [6] [7] [8] , there is an urgent need to develop an inhibitor of class C ESBLs or to discover new antibacterial drugs for these class C ESBLproducing clinical isolates. Such efforts could be aided considerably by the structural information on class C ESBLs highlighted above 13 . At present, a few academic research groups (such as our group and Shoichet's laboratory 14 ) and small pharmaceutical companies (for example, novexel 15 , which was spun out of Aventis) are seeking such novel β-lactamase inhibitors.
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